Table 2.
Transgenic platforms for the humanized immune mouse model
Name | Transgenic molecules | Advantages | Limitations | Reference |
---|---|---|---|---|
NBSGW | c-Kit | Without irradiation; development of erythropoiesis and platelet | Not reported | [56] |
NSG-SGM3 | SCF, GM-CSF, IL-3 | Stable HSCs engraftment; increased monocytes, macrophages and DCs | Impaired stem cell function; short-term reconstitution | [72] |
NOG-EXL | GM-CSF, IL-3 | Stable HSCs engraftment; increased monocytes, macrophages and DCs | Increased anemia | [73] |
MISTRG | GM-CSF, IL-3, M-CSF, TPO, SIRPα | Stable HSCs engraftment; increased monocytes, macrophages and DCs; improved NK cells development | Increased anemia; shorter lifespan | [62] |
NOG-dKO | β2mnull, IAβnull | Decreased GVHD | Less T-cell differentiation | [37] |
NSG-HLA | HLA class I and II | HLA-restricted B- and T-cell functions; antigen-specific IgG responses | Pre-selection of HLA in donor cells | [74,75] |